AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why

Drug patents don't last forever, so pharmaceutical companies are constantly looking for the next big treatment to broaden their total portfolio of offerings.When it was clear a few years ago that biosimilars for AbbVie's (ABBV 1.54%) Humira would be hitting the market, management knew it had work to do. Humira is the best-selling prescription drug in history, putting AbbVie on the map. But nothing lasts forever, and the company began taking steps to ensure its future success.First, AbbVie completed the bloc ...